Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2019

Candice L. Robinson, MD; Henry Bernstein, MD; José R. Romero, MD; Peter Szilagyi, MD


Morbidity and Mortality Weekly Report. 2019;68(5):112-114. 

In This Article

Changes Affecting Multiple Portions of the Schedule

The overall appearance of the 2019 child and adolescent schedule has been updated because of recommendations resulting from a recent evaluation of the child and adolescent immunization schedule. An internet survey of 249 pediatricians and family medicine physicians was conducted to assess their familiarity with the schedule, the environment in which the schedule is used, the frequency and circumstances of use, and their impressions and preferences on redesigned drafts of the child and adolescent immunization schedule. These changes have been applied to all portions of the immunization schedule, including the cover page, routine immunization schedule (Table 1), catch-up schedule (Table 2), medical indications for each vaccine (Table 3), and notes with details for each vaccine.

Cover Page. Changes to the cover page are as follows:

  • Guidance on how to use the schedule was added to the top of the document.

  • Live attenuated influenza vaccine (LAIV) was added to the vaccine table.

  • A Helpful Information section, which includes links to the ACIP recommendations, the General Best Practice Guidelines for Immunization, and the Manual for the Surveillance of Vaccine-Preventable Diseases, has been added.

Table 1. Changes to Table 1 (previously known as Figure 1) are as follows:

  • A separate row has been added for LAIV.

  • A purple bar has been added to the Hepatitis A (HepA) row at age 6–11 months to represent use in infant travelers.

  • Within the Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) row, the bar for persons aged 13–18 years has been split into a half green and half purple bar to represent catch-up vaccination and use in pregnant adolescents, respectively.

Table 2. Changes to Table 2 (previously known as Figure 2) are as follows:

  • Minor changes to the order in which guidance is presented in the Haemophilius influenzae type b and Pneumococcal conjugate rows were made. The criteria under which no further doses are needed are now presented first, followed by recommendation for those for whom additional doses are indicated.

Table 3. Changes to Table 3 (previously known as Figure 3) are as follows:

  • A new pink color has been added to the legend, which represents "Delay vaccination until after pregnancy if vaccine indicated." This color is used in the pregnancy column for human papillomavirus vaccine.

  • The Contraindicated and Precaution for vaccination boxes in the legend have been defined with narrative text.

  • A row for LAIV has been added.

  • The Pregnancy cell in the meningococcal B vaccine row has been changed to the orange Precaution for vaccination color.

Notes. The notes (previously known as footnotes) are presented in alphabetical order rather than linked by numerical superscripts as in previous years. Edits have been made throughout the Notes section to harmonize language between the child and adolescent schedule and the adult immunization schedule, where possible. In addition, the following content changes were made:

  • The HepA note was revised to include information regarding the use of combined HepA-HepB vaccine in persons aged ≥18 years. A section for international travel has been added with recommendations for vaccination of travelers aged 6–11 months and unvaccinated travelers aged ≥12 months. Homelessness also has been added as an indication for HepA vaccination.

  • The HepB note was revised to include information regarding the use of CpG-adjuvanted HepB vaccine and combination HepA-HepB vaccine in persons aged ≥18 years.

  • Within the IPV note, a bullet has been added regarding the use of combination vaccines that contain IPV.

  • The Influenza vaccines note has been updated to indicate that LAIV can be used during the 2018–19 influenza season. A Special Situations section has been added with information regarding vaccination of persons with a history of egg allergy and circumstances under which LAIV use is not recommended.

  • During mumps and meningococcal disease outbreaks, the Additional Information section at the beginning of the notes directs providers to their state or local health department for information regarding vaccination during an outbreak. Therefore, language regarding the use of measles, mumps, and rubella (MMR) vaccine in the setting of a mumps outbreak or the use of meningococcal (groups A, C, W-135, and Y) conjugate (MenACWY) and meningococcal group B (MenB) vaccines in the setting of meningococcal disease outbreaks has been removed from the MMR and meningococcal vaccine notes.

  • The Tdap note has been updated to indicate that those persons who received a dose of Tdap or diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) at age 7–10 years inadvertently or as part of the catch-up series should still receive the routine dose of Tdap at age 11–12 years. A link to information regarding use of Tdap/tetanus and diphtheria toxoids (Td) for wound prophylaxis also has been added.